Knowledge Hub · Lu-177 n.c.a.
Lu-177 is the workhorse therapeutic β⁻ emitter of contemporary theranostics — PSMA-617 for mCRPC, DOTATATE for NETs, FAPI for tumour-stroma protocols. What separates a good clinical batch from a marginal one is set upstream of the labelling kit: how much cold lutetium is in the matrix, how much Lu-177m metastable contamination tails into long-term organ dose, and how tightly the radionuclidic purity meets the pharmacopoeia. This page unpacks what "no-carrier-added" actually buys.
Why this matters
What "n.c.a." actually means
Lu-177 can be produced two ways. Carrier-added production (direct neutron capture on Lu-176 targets) ships a matrix dominated by stable Lu-175/176. n.c.a. production routes the activity through Yb-176 → Yb-177 → Lu-177, then a chemical separation strips the ytterbium parent — leaving a Lu fraction in which essentially every atom is Lu-177. At the labelling bench, the DOTATATE / PSMA / FAPI peptide does not have to compete against bulk cold lutetium for the chelation site.
Based on: Dash A. et al., Production of ¹⁷⁷Lu for targeted radionuclide therapy: a review. Nucl. Med. Biol. 2015.
Read source ↗Specific activity → labelling yield
Standard carrier-added Lu-177 typically lands around 600 GBq/mg. SHINE Medical n.c.a. ¹⁷⁷LuCl₃ delivers ≥3,000 GBq/mg at calibration with batch peaks near 3,700 GBq/mg. The ratio is roughly 5×. For the same therapeutic activity, n.c.a. lets the radiopharmacist label with five-fold less peptide mass — keeping the patient peptide dose low, the labelling yield high, and the tumour-to-background ratio clean on imaging.
Based on: Specific activity claims sourced to the SHINE FDA Drug Master File summary; benchmarked against EANM PRRT practical guidance.
Read source ↗Lu-177m — the kidney-dose argument
Carrier-added Lu-177 batches carry a metastable Lu-177m impurity (T½ ≈160 days). That long-lived contaminant contributes disproportionately to long-tail kidney dose during therapy and forces a long decay-store dwell for spent vials and patient excreta. n.c.a. production effectively eliminates Lu-177m — the spent-vial waste decays on the primary 6.65-day half-life, which is what the AERB-style decay-store rotation expects.
Based on: IAEA TECDOC-1955 Lu-177 production and quality; AERB Atomic Energy (Radiation Protection) Rules 2004.
Read source ↗208 keV imaging gamma
Lu-177 emits a 208 keV gamma (11 %) alongside the therapeutic β⁻. That is exactly the energy window a clinical SPECT camera maps for quantitative imaging. After each cycle, post-therapy SPECT/CT yields tumour and organ activity per voxel, feeding the dosimetry workflow EANM and AAPM TG-181 / TG-211 expect. n.c.a. activity per peptide is high enough to deliver clinical activity at low peptide mass — the imaging side stays clean.
Based on: EANM dosimetry guidance for radiopharmaceutical therapies; AAPM TG-181 PET/NM QA.
Read source ↗cGMP + FDA Drug Master File
SHINE Medical (Janesville, Wisconsin) produces the Lu-177 starting material under cGMP and ICH-Q7, with an FDA Drug Master File on file. For an Indian centre running an AERB-licensed theranostic programme, the upstream radionuclide dossier is already built — Saxsons supplies the AERB import licensing, sealed-source documentation and CDSCO-aligned paperwork on the India side.
Based on: ICH-Q7 Good Manufacturing Practice for Active Pharmaceutical Ingredients; FDA 21 CFR.
Read source ↗One n.c.a., three (and counting) targets
A centre running PRRT alone today can extend the same SHINE-produced Lu-177 supply chain to PSMA-617 when the prostate clinic comes online, and to FAPI when the pancreatic-stroma protocol gets ethics approval — without re-qualifying the radionuclide. One Saxsons import line, one calibration schedule, three (and counting) clinical programmes downstream.
Based on: Saxsons supply-chain framing; consistent with the SHINE multi-target labelling examples.
Read source ↗Specification snapshot
≥3,000
GBq/mg
Specific activity at calibration
≥99.9 %
Radionuclidic purity
Ph. Eur. compliant
6.65 d
Half-life
β⁻ + 208 keV imaging γ
Negligible
Lu-177m
Spent-vial waste decays in days
Scope of this page
This page covers the upstream n.c.a. Lu-177 starting material. Target-specific knowledge — DOTATATE labelling for NETs, PSMA-617 labelling for mCRPC, FAPI labelling for tumour-stroma protocols — lives on the per-target knowledge hubs linked from the Where Next section. Activity-level claims and specific-activity figures are sourced to the SHINE FDA Drug Master File summary; clinical-protocol claims are sourced to peer-reviewed literature and EANM / AAPM guidelines.
The IAEA, EANM and ICH documents that frame Lu-177 n.c.a. production, labelling and clinical use.
IAEA review of Lu-177 production routes, including the n.c.a. (Yb-176 → Yb-177 → Lu-177) pathway and quality-control expectations.
European Association of Nuclear Medicine procedural guidelines covering Lu-177 specific-activity, labelling-yield and dosimetry expectations.
International Council for Harmonisation GMP guideline that frames upstream Lu-177 manufacturing.
Indian regulatory framework for import, transport, decay-store and disposal of Lu-177 radionuclide consignments.
Where next
¹⁷⁷Lu-DOTATATE →
PRRT for NETs
Somatostatin-receptor-positive GEP-NETs, four-cycle protocol, theranostic pairing with Ga-68 DOTATATE.
¹⁷⁷Lu-PSMA-617 →
mCRPC theranostics
PSMA-positive metastatic castration-resistant prostate cancer, VISION trial framing, six-cycle protocol.
¹⁷⁷Lu-FAPI →
Tumour-stroma protocols
FAP-positive pancreatic, sarcoma and breast cancers — investigational, peer-reviewed pilot data emerging.